Rugby Player-Turned-Researcher Seeks Mechanisms Behind Prostate Cancer Metastases

Leigh Ellis, PhD, once seemed destined for a career intercepting passes as a professional rugby player. Now, the Dana-Farber researcher is devising plays to intercept prostate cancer cells before they become metastatic. These tactics could also potentially slow other genitourinary diseases, including kidney cancer. Ellis’ laboratory works to better understand the underlying genetic and epigenetic … Read more

After Cancer Treatment, Father and Daughter Come Out With an Even Stronger Bond

As father and daughter, there are many things Dennis Gorden and Becky Nutley share: a contagious smile, the instinct to help others, and a commitment to family, to name a few. But one thing they never imagined they would have in common was a cancer diagnosis. In 2014, routine blood work revealed that Becky Nutley, … Read more

Treating Cancer by Location or Genetic Markers: Which is Better?

In the past, treating cancers involved classifying them primarily by the organ or tissue where they arose – like the skin, the lungs, the breast, or the colon. Today, it’s often possible to identify the genes and proteins responsible for a tumor’s growth, and, in some cases, to offer a drug treatment that specifically targets … Read more

How Is Immunotherapy Used to Treat Bladder Cancer?

Treatments that improve the immune system’s ability to recognize and kill cancer cells are known as immunotherapy. For certain patients with advanced bladder cancer, immunotherapy is proving effective, and several immunotherapy drugs are approved for use in such patients. Currently approved treatments A checkpoint inhibitor is a drug — often made of antibodies — that … Read more

Online Tool Offers Guidance for Men with Non-Metastatic Prostate Cancer

Men diagnosed with non-metastatic prostate cancer now have access to a new tool on the TrueNTH USA website to help them prepare for their first meeting with a cancer physician. The tool, called Personal Patient Profile-Prostate (P3P), was created by Dana-Farber researchers and is now available to all men with non-metastatic prostate cancer though TrueNTH … Read more

Immunotherapy Beats Chemotherapy for Advanced Bladder Cancer Patients

The immunotherapy drug pembrolizumab (Keytruda) is the first therapy of any kind to improve survival in patients whose metastatic bladder cancer worsened after treatment with platinum-based chemotherapy. Keytruda proved so much better than chemotherapy in this “second-line” use that an international clinical trial was halted when the advantage became apparent. “This is very good news; … Read more

What Is ‘Watchful Waiting’ and When Is it Right for Prostate Cancer?

According to the American Cancer Society, more than 180,000 men will be diagnosed with prostate cancer this year, with African American men 60 percent more likely to develop the disease than other ethnic groups. Fortunately, the vast majority of prostate cancer diagnoses will be a slow-growing, highly treatable form of the disease. For many men diagnosed … Read more

Cancer Conversations Podcast—Episode #16: The Latest in Prostate Cancer Treatment and Research

Prostate cancer affects 230,000 men each year. Although diagnoses are increasing worldwide, most people die with prostate cancer and not of prostate cancer, according to Mark Pomerantz, MD, a medical oncologist in Dana-Farber’s Lank Center for Genitourinary Oncology. In this Cancer Conversations podcast episode, Pomerantz discusses genetics, risk factors, and the controversy surrounding the PSA … Read more

The Latest in Prostate Cancer Research and Treatment

Prostate cancer is the most common cancer affecting men in the United States, after skin cancer. Yet, “most men die with prostate cancer, not of prostate cancer,” says Mark Pomerantz, MD, a medical oncologist in Dana-Farber’s Lank Center for Genitourinary Oncology, who recently shared the latest in prostate cancer research and treatment during a live … Read more